Yoo Ga Young, Lee June, Hong Seok Beom, Kim Do Yeon
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Chest Surg. 2024 May 5;57(3):319-322. doi: 10.5090/jcs.23.132. Epub 2024 Jan 16.
Venovenous extracorporeal membrane oxygenation (VV ECMO) is often used in cases of severe respiratory failure, especially in patients considered for lung transplantation. However, because many lung diseases can ultimately result in right heart failure, the treatment of secondary right heart failure can present a challenge when the patient is already under VV ECMO support. In such cases, an oxygenated-right ventricular assist device (OxyRVAD) can be used. OxyRVAD is designed to maintain anterograde blood flow and prevent right ventricular distension. Moreover, the pulmonary arterial cannula can be inserted percutaneously. We report a case in which percutaneous OxyRVAD was successfully implemented to manage right heart failure in a patient with respiratory failure who was on VV ECMO.
静脉-静脉体外膜肺氧合（VV ECMO）常用于严重呼吸衰竭的病例，尤其是考虑进行肺移植的患者。然而，由于许多肺部疾病最终可导致右心衰竭，当患者已接受VV ECMO支持时，继发性右心衰竭的治疗可能会带来挑战。在这种情况下，可使用氧合右心室辅助装置（OxyRVAD）。OxyRVAD旨在维持顺行血流并防止右心室扩张。此外，肺动脉插管可经皮插入。我们报告了一例成功实施经皮OxyRVAD治疗呼吸衰竭且接受VV ECMO的患者右心衰竭的病例。
